nach oben

Journal of Genetic Counseling

Erschienen in:

01.08.2012 | Original Research

Delivering a Pharmacogenetic Service: Is There a Role for Genetic Counselors?

verfasst von: Alice Callard, William Newman, Katherine Payne

Erschienen in: Journal of Genetic Counseling | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Pharmacogenetics, the use of genetic information to direct safer and or more effective prescription of medication, is a relatively new clinical concept. Currently, there is no consensus regarding which healthcare professionals should deliver pharmacogenetic services. This study explored the opinions of genetic counselors about their potential role in delivering pharmacogenetic services. Semi-structured face-to-face interviews were conducted with 14 genetic counselors. Four vignettes describing pharmacogenetic testing scenarios were used to elicit views on specific clinical applications. Data were analysed using the constant comparative method. Opinions varied, but the majority of interviewees suggested that genetic counselors could have a role. However, participants suggested that additional training would be needed due to counselors’ limited knowledge of pharmacogenetics. Employing genetic counselors in a specialist role within a multidisciplinary clinic was suggested as a model of service delivery. Service models developed for pharmacogenetic testing may need to be adapted according to the issues presented by each type of test.

Nur mit Berechtigung zugänglich

Ashley, E. A., Butte, A. J., Wheeler, M. T., Chen, R., Klein, T. E., Dewey, F. E., et al. (2010). Clinical assessment incorporating a personal genome. Lancet, 375, 1525–1535.PubMedCrossRef

Bowling, A. (2002). Research Methods in Health: Investigating health and health services (2nd ed.). Maidenhead: Open University Press.

Bagos, P. G., Elefsinioti, A. L., Nikolopoulos, G. K., & Hamodrakas, S. J. (2007). The GNB3 C825T polymorphism and essential hypertension: a meta-analysis of 34 studies including 14,094 cases and 17,760 controls. Journal of Hypertension, 25, 487–500.PubMedCrossRef

Becquemont, L., Alfirevic, A., Amstutz, U., Brauch, H., Jacqz-Aigrain, E., Laurent-Puig, P., et al. (2011). Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics, 12(1), 113–124.

Buchanan, A., Califano, A., Kahn, J., McPherson, E., Robertson, J., & Brody, B. (2002). Pharmacogenetics: ethical issues and policy options. Kennedy Institute of Ethics Journal, 2, 1–15.CrossRef

Caldwell, J. (2001). The pharmacogenetic basis of adverse drug reactions. International Journal of Pharmaceutical Medicine, 15, 83–84.

Clemerson, J. P., Payne, K., Bissell, P., & Anderson, C. (2006). Pharmacogenetics, the next challenge for pharmacy? Pharmacy World & Science, 28, 126–130.CrossRef

Consortium on Pharmacogenetics (2002) Pharmacogenetics: Ethical and regulatory issues in research and clinical practice. Report of the Consortium on Pharmacogenetics Findings and Recommendations, 1–43.

Department of Health White Paper (2003). Our inheritance, our future. Realising the potential of genetics in the NHS. Presented to Parliament by the Secretary of State for Health by Command of Her Majesty, The Stationery Office, Norwich, 1–99.

Donnai, D. (2002). Genetic services. Clinical Genetics, 61, 1–6.PubMedCrossRef

Eccles, D. M., Evans, D. G., & Mackay, J. (2000). Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. UK Cancer Family Study Group (UKCFSG). Journal of Medical Genetics, 37(3), 203–209.PubMedCrossRef

Ellingrod, V. L., & Moline, J. (2007). Incorporating pharmacogenomics into practice. Journal of Pharmacy Practice, 20(3), 277–282.CrossRef

Evans, W. E., & McLeod, H. L. (2003). Pharmacogenomics: drug disposition, drug targets and side effects. The New England Journal of Medicine, 348(6), 538–549.PubMedCrossRef

Evans, W. E., & Relling, M. V. (1999). Pharmacogenomics: translating functional genomics into rational therapeutics. Science, 286, 487–491.PubMedCrossRef

Evans, W. E., & Relling, V. (2004). Moving towards individualised medicine with pharmacogenomics. Nature, 429, 464–468.PubMedCrossRef

Fargher, E. A., Tricker, K., Newman, W., Elliott, R., Roberts, S. A., Shaffer, J. L., et al. (2007). Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. Journal of Clinical Pharmacy and Therapeutics, 32, 187–195.PubMedCrossRef

Fargher, E. A., Eddy, C., Newman, W., Qasim, F., Tricker, K., Elliott, R. A., et al. (2007). Patients’ and healthcare professionals’ views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics, 8(11), 1511–1519.PubMedCrossRef

Finch, J. (1987). The vignette technique in survey research. Sociology, 21, 105–114.CrossRef

Frueh, F. W., & Gurwitz, D. (2004). From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the community. Pharmacogenomics, 5(5), 571–579.PubMedCrossRef

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine, 361(2), 123–134.PubMedCrossRef

Gardiner, S. J., & Begg, E. J. (2005). Pharmacogenetic testing for drug-metabolizing enzymes: is it happening in practice? Pharmacogenetics and Genomics, 15, 365–369.PubMedCrossRef

Goetz, M. P., Kamal, A., & Ames, M. M. (2008). Tamoxifen pharmacogenetics: the role of CYP2D6 as a predictor of drug response. Clinical Pharmacology, Therapy, 83(1), 160–166.CrossRef

Haga, S. B., & Burke, W. (2008). Pharmacogenetic testing: not as simple as it seems. Genetics in Medicine, 10(6), 391–395.

Hedgecoe, A. (2007). Education, ethics and knowledge deficits in clinical pharmacogenetics. Pharmacogenomics, 8(3), 267–270.PubMedCrossRef

Higgs, J., Gambhir, N., Ramsden, S. C., Poulton, K., & Newman, W. G. (2010). Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories. Genetic Testing and Molecular Biomarkers, 14(1), 121–125.PubMedCrossRef

Hopkins, M. M., Ibarreta, D., Gaisser, S., Enzing, C. M., Ryan, J., Martin, P. A., et al. (2006). Putting pharmacogenetics into practice. Nature Biotechnology, 24(4), 403–410.PubMedCrossRef

Kalow, W. (1956). Familial incidence of low pseudocholinesterase level. Lancet, 2, 576–577.CrossRef

Kiani, J. G., Saeed, M., Parvez, S. H., & Frossard, P. M. (2005). Association of G-protein beta 3 subunit gene (GNB3) T825 allele with type II diabetes. Neuro Endocrinology Letters, 26, 87–88.PubMed

Kinmonth, A. L., Reinhard, J., Bobrow, M., & Pauker, S. (1998). Implications for clinical services in Britain and the United States. BMJ, 316(7133), 767–770.PubMedCrossRef

Lash, T. J. (2010). Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy. Journal of Clinical Oncology, 28(8), 1273–1275.PubMedCrossRef

McLeod, H. L., & Silva, C. (2002). The thiopurine S-methyltransferase gene locus – implications for clinical pharmacogenomics. Pharmacogenomics, 3, 89–98.PubMedCrossRef

Melzer, D., Raven, A., Detmer, D. E., Ling, T. & Zimmern, R. L. (2003). My very own medicine: what must I know? Information policy of Pharmacogenetics Project. The Department of Public Health and Primary Care, University of Cambridge, 1–69.

Netzer, C., & Biller-Andorno, N. (2004). Pharmacogenetic testing, informed consent and the problem of secondary information. Bioethics, 18(4), 344–360.PubMedCrossRef

O’Daniel, J. M. (2010). The prospect of genome-guided preventative medicine: a need and opportunity for genetic counselors. Journal of Genetic Counseling, 19, 315–327.PubMedCrossRef

Ormond, K. E., Wheeler, M. T., Hudgins, L., Klein, T. E., Butte, A. J., Altman, R. B., et al. (2010). Challenges in the clinical application of whole-genome sequencing. Lancet, 375, 1749–1751.PubMedCrossRef

Payne, K., Fargher, E. A., Roberts, S. A., Tricker, K., Elliott, R. A., Ratcliffe, J., et al. (2011). Valuing pharmacogenetic testing services: a comparison of patients’ and healthcare professionals’ preferences. Value in Health, 14(1), 121–134.PubMedCrossRef

Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., et al. (2004). Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ, 329(7456), 15–19.PubMedCrossRef

Resta, R., Biesecker, B. B., Bennett, R. L., Blum, S., Hahn, S. E., Strecker, M. N., et al. (2006). A new definition of genetic counseling: National Society of Genetic Counselors’ task force report. Journal of Genetic Counseling, 15(2), 77–83.PubMedCrossRef

Robertson, J. A. (2001). Consent and privacy in pharmacogenetic testing. Nature Genetics, 28, 207–209.PubMedCrossRef

Rogausch, A., Prause, S., Schallenberg, A., Brockmoller, J., & Himmel, W. (2006). Patients’ and physicians’ perspectives on pharmacogenetic testing. Pharmacogenomics, 7(1), 49–59.PubMedCrossRef

Shah, J. (2004). Criteria influencing the clinical uptake of pharmacogenomic strategies. BMJ, 328, 1482–1486.PubMedCrossRef

Shields, A. E., Blumenthal, D., Weiss, K. B., Comstock, C. B., Currivan, D., & Lerman, C. (2005). Barriers to translating emerging genetic research on smoking into clinical practice. Perspectives of primary care physicians. Journal of General Internal Medicine, 20(2), 131–138.PubMedCrossRef

Strauss, A., & Corbin, J. (1990). Basics of qualitative research: Grounded theory procedures and techniques (2nd ed.). London: Sage.

Weinshilboum, R. (2003). Inheritance and drug response. The New England Journal of Medicine, 348, 529–537.PubMedCrossRef

Weinshilboum, R., & Wang, L. (2004). Pharmacogenomics: Bench to bedside. Nature Reviews. Drug Discovery, 3(9), 739–748.PubMedCrossRef

Wilkie, M. J., Smith, D., Reid, I. C., Day, R. K., Matthews, K., Wolf, C. R., et al. (2007). A splice site polymorphism in the G-protein beta subunit influences antidepressant efficacy in depression. Pharmacogenetics and Genomics, 17, 207–215.PubMedCrossRef

Titel: Delivering a Pharmacogenetic Service: Is There a Role for Genetic Counselors?
verfasst von: Alice Callard
William Newman
Katherine Payne
Publikationsdatum: 01.08.2012
Verlag: Springer US
Erschienen in: Journal of Genetic Counseling / Ausgabe 4/2012
Print ISSN: 1059-7700
Elektronische ISSN: 1573-3599
DOI: https://doi.org/10.1007/s10897-011-9415-4

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Rezidivierender Peritonsillarabszess nach Oralsex

02.05.2024 Peritonsillarabszess Kasuistik

Die erotischen Dimensionen von Peritonsillarabszessen scheinen eng begrenzt zu sein. Das heißt aber nicht, solche Abszesse und Erotik hätten nichts miteinander gemein, wie ein Fallbericht verdeutlicht.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

02.05.2024 DCK 2024 Kongressbericht

Die Hybrid-DRG-Verordnung soll dazu führen, dass mehr chirurgische Eingriffe ambulant durchgeführt werden, wie es in anderen Ländern schon länger üblich ist. Die gleiche Vergütung im ambulanten und stationären Sektor hatten Niedergelassene schon lange gefordert. Aber die Umsetzung bereitet ihnen doch Kopfzerbrechen.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Delivering a Pharmacogenetic Service: Is There a Role for Genetic Counselors?

Abstract

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Rezidivierender Peritonsillarabszess nach Oralsex

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

Update Gynäkologie

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2012

Giving and Withholding of Information following Genomic Screening: Challenges Identified in a Study of Primary Care Physicians in Estonia

Identification of Individuals at Risk for Lynch Syndrome Using Targeted Evaluations and Genetic Testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer Joint Practice Guideline

In Memoriam: Rose Grobstein (1917–2011)

Breaking Difficult News in a Cross-cultural Setting: a Qualitative Study about Latina Mothers of Children with Down Syndrome

Effects of a Documentary Film on Public Stigma Related to Mental Illness Among Genetic Counselors

Counseling Adolescents and the Challenges for Genetic Counselors

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

Rezidivierender Peritonsillarabszess nach Oralsex

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Ambulantisierung: Erste Erfahrungen mit dem Hybrid-DRG

Update Gynäkologie